Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reiterated by stock analysts at Stifel Nicolaus in a research report issued to clients and investors on Thursday. They presently have a GBX 271 ($3.54) target price on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 125.83% from the stock’s previous close.

Shares of Ergomed PLC (LON:ERGO) opened at 121.125 on Thursday. Ergomed PLC has a 52-week low of GBX 117.00 and a 52-week high of GBX 176.50. The firm’s market capitalization is GBX 34.82 million. The company’s 50-day moving average price is GBX 119.94 and its 200-day moving average price is GBX 136.77.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Ergomed PLC Company Profile

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with's FREE daily email newsletter.